ADDI launches new Workbench to foster greater global research innovation and accelerate breakthroughs in Alzheimer’s disease and related dementias

The Alzheimer’s Disease Data Initiative (ADDI) has launched its Alzheimer’s disease (AD) Workbench, a cloud-based platform for scientists to accelerate discoveries and innovations for AD and related dementias. ADDI is a new global effort that aims to advance AD innovation by connecting researchers with the data needed to generate insights and inform the development of improved…

New paper investigating the prediction of Alzheimer’s disease biomarker status

The EPAD team has published a new paper entitled “Prediction of Alzheimer’s disease biomarker status defined by the ‘ATN framework’ among cognitively healthy individuals: results from the EPAD longitudinal cohort study” in the journal Alzheimer’s Research Therapy. In this paper, authors from the University of Oxford and the Alzheimer Center Amsterdam tested the predictive utility of…

The Alzheimer’s Disease Data Initiative supports EPAD

The Alzheimer’s Disease Data Initiative (ADDI) aims to move Alzheimer’s disease (AD) innovation further and faster by connecting researchers with the data they need to generate insights to inform development of new, better treatments and diagnostic tools for AD and related dementias. We are pleased that ADDI is supporting the EPAD project. In 2016, EPAD…

EPAD presents at the 30th Alzheimer Europe conference

The 30th Alzheimer Europe Conference (#30AEC) “Dementia in a changing world” was held online from 20-22 October 2020. Almost 800 participants, from 42 countries, attended the conference, which boasted 260 speakers and 100 poster presentations, sharing their research, projects and experiences in an atmosphere of collaboration and solidarity, against the backdrop of the global COVID-19…

Interview with Marta Milà Alomà

Could you tell us a bit about you and your work? My background lies in the fields of neurobiology and neuropsychology, and I am currently a PhD student at Barcelonabeta Brain Research Center. My research focuses on the study of fluid biomarker profiles in preclinical Alzheimer’s disease, as well as on the effect of modifiable…

New paper on the EPAD participant panel experience

On 15 October, a new paper entitled “Involving research participants in a pan-European research initiative: the EPAD participant panel experience” has been published in the journal Research Involvement and Engagement. One of the founding goals of the EPAD programme was to involve participants as research partners. EPAD set up a series of ‘participant panels’ in…

EPAD publishes a new paper on cognitive dispersion

The EPAD team has published a new paper entitled “Cognitive Dispersion is not Associated with Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Results from the European Prevention of Alzheimer’s Dementia (EPAD) v500.0 Cohort” in the journal of Alzheimer’s disease. Abstract: Background: Cognitive dispersion, variation in performance across cognitive domains, is posited as a non-invasive and cost-effective…

New ERC starting grant to identify age-related human blood factors as a therapeutic target for Alzheimer’s disease

The European Research Council has awarded an Early Career Research (ERC) starting grant to the neurologist Marc Suárez-Calvet, MD, PhD, who will use data from the EPAD Longitudinal Cohort Study for his new project entitled “Identification of age-related Human Blood factors as a therapeutic target for Alzheimer’s disease” (acronym: HeBe). The overall aim of the…